K Sartorius1, B Sartorius2, C Aldous3, P S Govender3, T E Madiba3. 1. Faculty of Commerce, University of the Witwatersrand, Johannesburg, South Africa; Public Health Medicine, School of Nursing and Public Health, University of the Kwazulu-Natal, Durban, South Africa; SAMRC/UKZN Gastrointestinal Cancer Research Centre, South Africa. Electronic address: Kurt.Sartorius@wits.ac.za. 2. Public Health Medicine, School of Nursing and Public Health, University of the Kwazulu-Natal, Durban, South Africa; SAMRC/UKZN Gastrointestinal Cancer Research Centre, South Africa. 3. School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa(1); SAMRC/UKZN Gastrointestinal Cancer Research Centre, South Africa.
Abstract
PURPOSE: The problems of screening costs, as well as poor data, potentially lead to the underestimation of the incidence of hepatocellular carcinoma (HCC). In particular, this is problematic in developing countries with limited resources and poor data. The study develops a model to inform policy makers of the true incidence and potential extra cost of HCC in a developing country context. METHODS: Using Globocan 2012 data, we employed an ecological correlation design at country level to associate HCC incidence data with relevant determinant data like HBV-HCV and other exposure factors. A Poisson regression model was used to estimate potentially missed incident cases of HCC by country and region based on the country risk factor covariate values. RESULTS: The results indicated that HBV and HCV prevalence were significantly associated with HCC incidence (p<0.001) and potentially accounted for 94%% of incident HCC in 2012. We estimated a total of 120,772 potentially missed incident HCC cases in 2012. These cases are largely predicted for South Asia (>21,000), North Asia (>15,000), Western Africa (14,500) and Eastern Africa (12,500). CONCLUSIONS: Developing countries, with poorer quality data and a high historical burden of hepatitis, were predicted to have the majority of missed HCC cases in 2012 based on our model. These countries are, therefore, less able to detect, budget for or manage HCC. The high cost of HCC treatment, as well as its economic implications, poses a challenge in resource poor settings.
PURPOSE: The problems of screening costs, as well as poor data, potentially lead to the underestimation of the incidence of hepatocellular carcinoma (HCC). In particular, this is problematic in developing countries with limited resources and poor data. The study develops a model to inform policy makers of the true incidence and potential extra cost of HCC in a developing country context. METHODS: Using Globocan 2012 data, we employed an ecological correlation design at country level to associate HCC incidence data with relevant determinant data like HBV-HCV and other exposure factors. A Poisson regression model was used to estimate potentially missed incident cases of HCC by country and region based on the country risk factor covariate values. RESULTS: The results indicated that HBV and HCV prevalence were significantly associated with HCC incidence (p<0.001) and potentially accounted for 94%% of incident HCC in 2012. We estimated a total of 120,772 potentially missed incident HCC cases in 2012. These cases are largely predicted for South Asia (>21,000), North Asia (>15,000), Western Africa (14,500) and Eastern Africa (12,500). CONCLUSIONS: Developing countries, with poorer quality data and a high historical burden of hepatitis, were predicted to have the majority of missed HCC cases in 2012 based on our model. These countries are, therefore, less able to detect, budget for or manage HCC. The high cost of HCC treatment, as well as its economic implications, poses a challenge in resource poor settings.
Authors: Marvin M Festag; Julia Festag; Simon P Fräßle; Theresa Asen; Julia Sacherl; Sophia Schreiber; Martin A Mück-Häusl; Dirk H Busch; Karin Wisskirchen; Ulrike Protzer Journal: Mol Ther Date: 2019-02-10 Impact factor: 11.454
Authors: Brian McMahon; Joan Block; Timothy Block; Chari Cohen; Alison A Evans; Anu Hosangadi; W Thomas London; Morris Sherman Journal: J Natl Cancer Inst Date: 2015-11-30 Impact factor: 13.506
Authors: Alok R Singh; Shweta Joshi; Adam M Burgoyne; Jason K Sicklick; Sadakatsu Ikeda; Yuko Kono; Joseph R Garlich; Guillermo A Morales; Donald L Durden Journal: Mol Cancer Ther Date: 2016-08-05 Impact factor: 6.261